Emcure Pharmaceuticals Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter

The Emcure Pharmaceuticals Q2 results FY27 announcement is the next scheduled earnings event for Emcure Pharmaceuticals Ltd., a pharmaceutical company making and selling branded generics, injectables and biosimilars for the Indian market and for export. The stock traded at Rs 1,914.40 on the NSE on 9 September 2026, down 0.59% from the previous close of Rs 1,925.80, about 6.5% below its 52-week high of Rs 2,048.00 and 51.9% above its 52-week low of Rs 1,260.00.

What makes the Emcure Pharmaceuticals Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 2,270.00 crore of revenue and a profit of Rs 251.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 2,580.00 crore and a profit of Rs 292.00 crore. Everything below is built from those reported figures rather than from any forecast.

Click Here – Get Free Investment Predictions

When Is the Emcure Pharmaceuticals Q2 Results FY27 Date?

The Emcure Pharmaceuticals Q2 results date for FY27 is not confirmed. As of 9 September 2026, Emcure Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.

What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Emcure Pharmaceuticals Q2 results date becomes public through that filing rather than through any advance announcement.

The Emcure Pharmaceuticals Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Emcure Pharmaceuticals.

Emcure Pharmaceuticals Q2 Results Expectations: What the Market Is Actually Tracking

No verified analyst estimate for the Emcure Pharmaceuticals Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Emcure Pharmaceuticals. The Emcure Pharmaceuticals Q2 results watchlist below is built from what the company has actually reported and disclosed.

The first is revenue, which rose in every one of the five quarters from Rs 2,101 crore to Rs 2,580 crore. The September 2025 base of Rs 2,270 crore is about 12% below the most recent quarter.

The second is the operating margin, which was 21% in both September 2025 and Q1 FY27 and stayed inside a 19% to 21% band throughout. Operating profit rose from Rs 475 crore to Rs 532 crore over the same period.

The third is other income, which was negative Rs 36 crore in December 2025 against Rs 0 crore to Rs 14 crore in the other four quarters. That single line cut pre-tax profit to Rs 314 crore in a quarter whose operating profit was the second highest of the five.

Check Emcure Pharmaceuticals Ltd. Live Fundamentals on the Univest Screener

Emcure Pharmaceuticals Q2 Results Preview: The Q1 FY27 Actuals It Builds On

Emcure Pharmaceuticals Ltd. reported revenue of Rs 2,580.00 crore in Q1 FY27, up 22.80% from Rs 2,101.00 crore in Q1 FY26, and a profit of Rs 292.00 crore at the net level, up 35.81% from Rs 215.00 crore in Q1 FY26. These are reported actuals, not estimates.

Sequentially, revenue was up 4.45% over the March 2026 quarter figure of Rs 2,470.00 crore, and net profit was up 19.67% from Rs 244.00 crore in Q4 FY26. Operating margin stood at 21% in Q1 FY27 against 21% in the September 2025 quarter, which is the comparison the Emcure Pharmaceuticals Q2 results print will be read against.

Q2 FY26 Base: The Comparison Emcure Pharmaceuticals Q2 Results FY27 Must Beat

Emcure Pharmaceuticals Ltd. reported revenue of Rs 2,270.00 crore and a profit of Rs 251.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Emcure Pharmaceuticals Q2 results preview.

Net profit in that base quarter was below the Rs 292.00 crore just reported for Q1 FY27, so the year-on-year comparison starts from a manageable level. Revenue of Rs 2,270.00 crore sits below the Rs 2,580.00 crore of the June 2026 quarter, which frames how much sequential movement the Emcure Pharmaceuticals Q2 results print needs to show growth.

Emcure Pharmaceuticals Quarterly Results Trend Over the Last Four Quarters

Quarter	Revenue (Rs Cr)	Net Profit (Rs Cr)
Q2 FY26 (Sep 2025)	2,270.00	251.00
Q3 FY26 (Dec 2025)	2,363.00	231.00
Q4 FY26 (Mar 2026)	2,470.00	244.00
Q1 FY27 (Jun 2026)	2,580.00	292.00

Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company's exchange filings, and they are the only basis this Emcure Pharmaceuticals Q2 results preview uses.

Revenue across those four quarters ranged from Rs 2,270.00 crore to Rs 2,580.00 crore, and net profit from Rs 231.00 crore to Rs 292.00 crore. That spread is the honest context for the Emcure Pharmaceuticals Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.

Key Factors That Could Shape Emcure Pharmaceuticals Q2 Results FY27

The Emcure Pharmaceuticals Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Emcure Pharmaceuticals has already reported.

Domestic Brands Against Exports

Branded generics sold in India carry different economics from regulated market exports and from the injectables and biosimilars business. The therapy and geography mix disclosed with the results explains the margin more precisely than the revenue figure does.

Interest Cost Is Rising

Borrowings rose from about Rs 1,023 crore in March 2025 to Rs 1,521 crore in March 2026, roughly 49% in a year, and quarterly interest went from Rs 27 crore to Rs 46 crore across the five quarters. That climb is worth watching against a steady operating margin.

Consistent Returns at a Full Multiple

Return on equity stands at 20.10% with a debt to equity ratio of 0.31. The stock trades at a price to earnings ratio of 35.29 and a price to book ratio of 7.33, above both its 50-day average of Rs 1,887.43 and its 200-day average of Rs 1,640.57.

Emcure Pharmaceuticals Q2 Results FY27: Share Price and Valuation Going Into the Print

Emcure Pharmaceuticals share price today is Rs 1,914.40 on the NSE, down Rs 11.40 or 0.59% from the previous close of Rs 1,925.80 on 9 September 2026, ahead of the Emcure Pharmaceuticals Q2 results announcement.

Metric	Value (9 September 2026)
NSE Symbol	EMCURE
Current Market Price	Rs 1,914.40
52-Week High	Rs 2,048.00
52-Week Low	Rs 1,260.00
Market Capitalisation	Rs 36,306 crore
PE Ratio	35.29
PB Ratio	7.33
EPS (TTM)	Rs 54.25
Book Value per Share	Rs 261.00
Debt to Equity	0.31
Return on Equity	20.10%
50-Day Moving Average	Rs 1,887.43
200-Day Moving Average	Rs 1,640.57
RSI (14)	57.28

The stock trades above both its 50-day average of Rs 1,887.43 and its 200-day average of Rs 1,640.57, with a 14-day RSI of 57.28. None of this is a view on where the shares go once the Emcure Pharmaceuticals Q2 results are announced, and no price target is offered here.

Download the Univest iOS App or Univest Android App to track Emcure Pharmaceuticals Ltd. live price and quarterly earnings updates.

What Investors Should Watch When Emcure Pharmaceuticals Q2 Results Are Announced

Four lines carry most of the information in a company of this size, and reading them in order keeps the Emcure Pharmaceuticals Q2 results print in proportion.

1. Revenue against the Rs 2,270.00 crore reported in the September 2025 base quarter
2. Net profit against a profit of Rs 251.00 crore in that same quarter
3. Operating margin against 21% in Q1 FY27
4. Any exceptional item, provision or one-off gain disclosed alongside the numbers

A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Emcure Pharmaceuticals Q2 results announcement should be read together with the notes to the results rather than the headline alone.

Conclusion on Emcure Pharmaceuticals Q2 Results FY27

The Emcure Pharmaceuticals Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Emcure Pharmaceuticals Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.

On that basis the Emcure Pharmaceuticals Q2 results FY27 print faces a base of Rs 2,270.00 crore in revenue and a profit of Rs 251.00 crore, with the most recent quarter having delivered Rs 2,580.00 crore and a profit of Rs 292.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Emcure Pharmaceuticals, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.

FAQs on Emcure Pharmaceuticals Q2 Results FY27

What is the Emcure Pharmaceuticals Q2 results date for FY27?

Ans. The Emcure Pharmaceuticals Q2 results date for FY27 is not confirmed. Emcure Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE as of 9 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.

What quarter do the Emcure Pharmaceuticals Q2 results 2026 cover?

Ans. The Emcure Pharmaceuticals Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Emcure Pharmaceuticals Ltd. reports revenue, operating profit and net profit for that period, and the Emcure Pharmaceuticals Q2 results filing also carries the notes to the accounts.

What were the Emcure Pharmaceuticals Q1 FY27 results?

Ans. Emcure Pharmaceuticals Ltd. reported revenue of Rs 2,580.00 crore in Q1 FY27 and a profit of Rs 292.00 crore at the net level. Revenue was up 22.80% versus Q1 FY26 and net profit was up 35.81% from Rs 215.00 crore in Q1 FY26.

What were Emcure Pharmaceuticals Q2 FY26 results in the September 2025 quarter?

Ans. Emcure Pharmaceuticals Ltd. reported revenue of Rs 2,270.00 crore and a profit of Rs 251.00 crore in Q2 FY26. Operating margin was 21%. Those figures form the base for the Emcure Pharmaceuticals Q2 results FY27 comparison.

What are the main Emcure Pharmaceuticals Q2 results expectations this quarter?

Ans. No verified analyst estimate is publicly available. The Emcure Pharmaceuticals Q2 results expectations centre on revenue against the Rs 2,270.00 crore base, net profit against a profit of Rs 251.00 crore, operating margin against 21% in Q1 FY27, and any exceptional item disclosed with the numbers.

What is Emcure Pharmaceuticals share price today ahead of the Q2 earnings?

Ans. Emcure Pharmaceuticals share price is Rs 1,914.40 on the NSE as of 9 September 2026, down 0.59% from Rs 1,925.80. The stock is about 6.5% below its 52-week high of Rs 2,048.00 and 51.9% above its 52-week low of Rs 1,260.00, at a market capitalisation of Rs 36,306 crore.

Is Emcure Pharmaceuticals a good stock to buy before the Q2 results?

Ans. This article does not offer a buy, sell or hold recommendation on Emcure Pharmaceuticals Ltd. The stock trades at a price-to-book ratio of 7.33 with a return on equity of 20.10%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.